[Cerebrospinal fluid filtration as experimental therapy in therapy refractory psychoses in Borna disease virus seropositive patients. Therapeutic effects, findings].

According to previous investigations, mild Borna disease virus encephalitis may underlie a subgroup of affective or schizophrenic type psychoses. And virus-induced immune pathology may underlie even a larger subgroup of psychoses. We treated BDV seropositive patients suffering from therapy resistant schizophrenic or affective spectrum psychoses by cerebrospinal fluid filtration (CSFF) in an experimental add-on treatment.

[CSF Filtration as Experimental Therapy in Therapyresistant Psychoses in Borna Disease Virus-Seropositive Patients].

According to previous investigations, mild Borna disease virus encephalitis may underlie a subgroup of affective or schizophrenic type psychoses. And virus-induced immune pathology may underlie even a larger subgroup of psychoses. We treated BDV seropositive patients suffering from therapy resistant schizophrenic or affective spectrum psychoses by cerebrospinal fluid filtration (CSFF) in an experimental add-on treatment.

The endogenous pentapeptide QYNAD induces acute conduction block in the isolated rat sciatic nerve.

Reversible block of sodium channels by endogenous substances was claimed to account for the fast relapses and remissions seen in demyelinating autoimmune disorders. The pentapeptide QYNAD, isolated from the cerebrospinal fluid from patients with multiple sclerosis (MS), blocked Na+ channels in various types of cultured cells. We show that 100 microM QYNAD bath-applied to isolated rat sciatic nerve causes the amplitude and area of the compound nerve action potential to decrease by 30-40%, while the latency increases.

CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial.

Objective: To compare CSF filtration (CSFF) and plasma exchange (PE) in the treatment of patients with Guillain-Barré syndrome (GBS).

Methods: In a prospective controlled clinical trial, 37 patients with acute GBS were randomized to receive either CSFF or PE. Inclusion criteria were fulfillment of National Institute of Neurological and Communicative Disorders and Stroke criteria and disability to walk >5 m unassisted.